Reversible changes in pancreatic islet structure and function produced by elevated blood glucose

Nature Communications

Volumn 5, Issue , 2014, Pages

  Brereton, Melissa F ^a   Iberl, Michaela ^a   Shimomura, Kenju ^a   Zhang, Quan ^a   Adriaenssens, Alice E ^b   Proks, Peter ^a   Spiliotis, Ioannis I ^a   Dace, William ^a   Mattis, Katia K ^a   Ramracheya, Reshma ^a   Gribble, Fiona M ^b   Reimann, Frank ^b   Clark, Anne ^a   Rorsman, Patrik ^a   Ashcroft, Frances M ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM); GLIBENCLAMIDE; GLUCAGON; GLUCOSE; INSULIN; SULFONYLUREA DERIVATIVE; ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; GLUCOSE BLOOD LEVEL; INWARDLY RECTIFYING POTASSIUM CHANNEL; INWARDLY RECTIFYING POTASSIUM CHANNEL SUBUNIT KIR6.2;

DIABETES; GENE EXPRESSION; GENETIC MARKER; GLUCOSE; SECRETION;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DIABETES MELLITUS; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HYPERGLYCEMIA; IN VITRO STUDY; IN VIVO STUDY; INSULIN TREATMENT; MOUSE; NONHUMAN; PANCREAS FUNCTION; PANCREAS ISLET; PANCREAS ISLET BETA CELL; PROTEIN STRUCTURE; ULTRASTRUCTURE; ANIMAL; ANTAGONISTS AND INHIBITORS; DIABETES MELLITUS, EXPERIMENTAL; DISEASE MODEL; DRUG EFFECTS; ELECTROPHYSIOLOGY; GENETICS; HUMAN; METABOLISM; MUTATION; PATHOLOGY; PROCEDURES; TRANSGENIC MOUSE;

ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; DISEASE MODELS, ANIMAL; ELECTROPHYSIOLOGY; GLYBURIDE; HUMANS; HYPERGLYCEMIA; INSULIN; ISLETS OF LANGERHANS; KATP CHANNELS; MICE, TRANSGENIC; MUTATION; POTASSIUM CHANNELS, INWARDLY RECTIFYING;

EID: 84907337110     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms5639     Document Type: Article

References (45)

1. Ashcroft, F. M. & Rorsman, P. Diabetes mellitus and the beta cell: the last ten years. Cell 148, 1160-1171 (2012).
2. Clark, A., Jones, L. C., de Koning, E., Hansen, B. C. & Matthews, D. R. Decreased insulin secretion in type 2 diabetes: a problem of cellular mass or functionDiabetes 50(Suppl 1): S169-S171 (2001). (Pubitemid 32148246)
3. Costes, S., Langen, R., Gurlo, T., Matveyenko, A. V. & Butler, P. C. beta-Cell failure in type 2 diabetes: a case of asking too much of too fewDiabetes 62, 327-335 (2013).
4. Weir, G. C. & Bonner-Weir, S. Islet beta cell mass in diabetes and how it relates to function, birth, and death. Ann. N.Y. Acad. Sci. 1281, 92-105 (2013).
5. Schuit, F., Flamez, D., De Vos, A. & Pipeleers, D. Glucose-regulated gene expression maintaining the glucose-responsive state of beta-cells. Diabetes 51(Suppl 3): S326-S332 (2002). (Pubitemid 35403412)
6. Lee, A. W. & Cox, R. D. Use of mouse models in studying type 2 diabetes mellitus. Expert. Rev. Mol. Med. 13, e1 (2011).
7. Ashcroft, F. M., Harrison, D. E. & Ashcroft, S. J. Glucose induces closure of single potassium channels in isolated rat pancreatic beta-cells. Nature 312, 446-448 (1984). (Pubitemid 15217837)
8. Ashcroft, F. M. & Rorsman, P. KATP channels and islet hormone secretion: new insights and controversies. Nat. Rev. Endocrinol. 9, 660-669 (2013).
9. Flanagan, S. E. et al. Update of mutations in the genes encoding the pancreatic beta-cell KATP channel subunits Kir6.2 (KCNJ11) and sulfonylurea receptor 1 (ABCC8) in diabetes mellitus and hyperinsulinism. Hum. Mutat. 30, 170-180 (2009).
10. Gloyn, A. L. et al. Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes. New Engl. J. Med. 350, 1838-1849 (2004). (Pubitemid 38917250)
11. Hattersley, A. T. & Ashcroft, F. M. Activating mutations in Kir6.2 and neonatal diabetes: new clinical syndromes, new scientific insights, and new therapy. Diabetes 54, 2503-2513 (2005). (Pubitemid 41233571)
12. Girard, C. A. et al. Expression of an activating mutation in the gene encoding the KATP channel subunit Kir6.2 in mouse pancreatic beta cells recapitulates neonatal diabetes. J. Clin. Invest. 119, 80-90 (2009).
13. Koster, J. C., Marshall, B. A., Ensor, N., Corbett, J. A. & Nichols, C. G. Targeted overactivity of beta cell KATP channels induces profound neonatal diabetes. Cell 100, 645-654 (2000).
14. Remedi, M. S. et al. Secondary consequences of beta cell inexcitability: identification and prevention in a murine model of KATP-induced neonatal diabetes mellitus. Cell Metab. 9, 140-151 (2009).
15. Proks, P., Girard, C. & Ashcroft, F. M. Functional effects of KCNJ11 mutations causing neonatal diabetes: enhanced activation by MgATP. Hum. Mol. Genet. 14, 2717-2726 (2005). (Pubitemid 41300644)
16. Zung, A., Glaser, B., Nimri, R. & Zadik, Z. Glibenclamide treatment in permanent neonatal diabetes mellitus due to an activating mutation in Kir6.2. J. Clin. Endocrinol. Metab. 89, 5504-5507 (2004). (Pubitemid 39518433)
17. Gribble, F. M. & Reimann, F. Sulphonylurea action revisited: the post-cloning era. Diabetologia 46, 875-891 (2003). (Pubitemid 36961311)
18. Pearson, E. R. et al. Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. New Engl. J. Med. 355, 467-477 (2006). (Pubitemid 44162274)
19. Henquin, J. C. Regulation of insulin secretion: a matter of phase control and amplitude modulation. Diabetologia 52, 739-751 (2009).
20. Klupa, T. et al. Efficacy and safety of sulfonylurea use in permanent neonatal diabetes due to KCNJ11 gene mutations: 34-month median follow-up. Diabetes Technol. Ther. 12, 387-391 (2010).
21. Remedi, M. S., Agapova, S. E., Vyas, A. K., Hruz, P. W. & Nichols, C. G. Acute sulfonylurea therapy at disease onset can cause permanent remission of KATPinduced diabetes. Diabetes 60, 2515-2522 (2011).
22. Marselli, L. et al. Are we overestimating the loss of beta cells in type 2 diabetesDiabetologia 57, 362-365 (2014).
23. Talchai, C., Xuan, S., Lin, H. V., Sussel, L. & Accili, D. Pancreatic beta cell dedifferentiation as a mechanism of diabetic beta cell failure. Cell 150, 1223-1234 (2012).
24. Gopel, S. O. et al. Regulation of glucagon release in mouse-cells by KATP channels and inactivation of TTX-sensitive Na\+ channels. J. Physiol. 528, 509-520 (2000).
25. Plant, T. D. Na\+ currents in cultured mouse pancreatic B-cells. Pflugers Arch. 411, 429-435 (1988).
26. Artner, I. et al. MafB: an activator of the glucagon gene expressed in developing islet alpha-and beta-cells. Diabetes 55, 297-304 (2006). (Pubitemid 43343256)
27. Collombat, P. et al. Embryonic endocrine pancreas and mature beta cells acquire alpha and PP cell phenotypes upon Arx misexpression. J. Clin. Invest. 117, 961-970 (2007). (Pubitemid 46556752)
28. Spijker, H. S. et al. Conversion of mature human beta-cells into glucagonproducing alpha-cells. Diabetes 62, 2471-2480 (2013).
29. Dhawan, S., Georgia, S., Tschen, S. I., Fan, G. & Bhushan, A. Pancreatic beta cell identity is maintained by DNA methylation-mediated repression of Arx. Dev. Cell 20, 419-429 (2011).
30. Gao, T. et al. Pdx1 maintains beta cell identity and function by repressing an alpha cell program. Cell Metab. 19, 259-271 (2014).
31. Thorel, F. et al. Conversion of adult pancreatic alpha-cells to beta-cells after extreme beta-cell loss. Nature 464, 1149-1154 (2010).
32. Laybutt, D. R. et al. Critical reduction in beta-cell mass results in two distinct outcomes over time. Adaptation with impaired glucose tolerance or decompensated diabetes. J. Biol. Chem. 278, 2997-3005 (2003). (Pubitemid 36801207)
33. Laybutt, D. R. et al. Influence of diabetes on the loss of beta cell differentiation after islet transplantation in rats. Diabetologia 50, 2117-2125 (2007). (Pubitemid 47373842)
34. Schaffer, A. E. et al. Nkx6.1 controls a gene regulatory network required for establishing and maintaining pancreatic Beta cell identity. PLoS Genet. 9, e1003274 (2013).
35. Guo, S. et al. Inactivation of specific beta cell transcription factors in type 2 diabetes. J. Clin. Invest. 123, 3305-3316 (2013).
36. Yoneda, S. et al. Predominance of beta-cell neogenesis rather than replication in humans with an impaired glucose tolerance and newly diagnosed diabetes. J. Clin. Endocrinol. Metab. 98, 2053-2061 (2013).
37. Wang, Z., York, N. W., Nichols, C. G. & Remedi, M. S. Pancreatic beta cell dedifferentiation in diabetes and redifferentiation following insulin therapy. Cell Metab. 19, 872-882 (2014).
38. Lim, E. L. et al. Reversal of type 2 diabetes: normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol. Diabetologia 54, 2506-2514 (2011).
39. Kulkarni, R. N. et al. Tissue-specific knockout of the insulin receptor in pancreatic beta cells creates an insulin secretory defect similar to that in type 2 diabetes. Cell 96, 329-339 (1999). (Pubitemid 29077587)
40. Dor, Y., Brown, J., Martinez, O. I. & Melton, D. A. Adult pancreatic beta-cells are formed by self-duplication rather than stem-cell differentiation. Nature 429, 41-46 (2004). (Pubitemid 38620543)
41. Luche, H., Weber, O., Nageswara Rao, T., Blum, C. & Fehling, H. J. Faithful activation of an extra-bright red fluorescent protein in "knock-in" Cre-reporter mice ideally suited for lineage tracing studies. Eur. J. Immunol. 37, 43-53 (2007). (Pubitemid 46128785)
42. Shimomura, K. et al. A mouse model of human hyperinsulinism produced by the E1506K mutation in the sulphonylurea receptor SUR1. Diabetes 62, 3797-3806 (2013).
43. Reimann, F. et al. Glucose sensing in L cells: a primary cell study. Cell Metab. 8, 532-539 (2008).
44. Gopel, S., Kanno, T., Barg, S., Galvanovskis, J. & Rorsman, P. Voltage-gated and resting membrane currents recorded from B-cells in intact mouse pancreatic islets. J. Physiol. 521(Pt 3): 717-728 (1999). (Pubitemid 30042784)
45. Zhang, Q. et al. R-type Ca2\+-channel-evoked CICR regulates glucose-induced somatostatin secretion. Nat. Cell Biol. 9, 453-460 (2007). (Pubitemid 46511079)